This paper is part of a series of 3 publications and describes the non-clinical and clinical assessment performed to fulfill the regulatory requirement per Art. 6 (2) of the EU Tobacco Products Directive 2014/40/EU; under which Member States shall require manufacturers and importers of cigarettes and roll-your-own tobacco containing an additive that is included in the priority list established by Commission Implementing Decision (EU) 2016/787 to carry out comprehensive studies. The Directive requires manufacturers and importers of cigarettes and Roll Your Own tobacco to examine for each additive whether it; contributes to and increases the toxicity or addictiveness of tobacco products to a significant or measurable degree; if it leads to a characterizing flavor of the product; if it facilitates inhalation or nicotine uptake, and if it results in the formation of CMR (carcinogenic, mutagenic and reprotoxic) constituents and if these substances increase the CMR properties of the respective tobacco product to a significant or measurable degree. This publication gives an overview on comprehensive smoke chemistry, in vitro toxicity, and human clinical studies commissioned by the members of the Priority Additives Tobacco Consortium to independent Contract Research Organizations (CROs) where the emissions of test cigarettes containing priority additives were compared to emissions emerging from an additive-free reference cigarette. Whilst minor changes in smoke chemistry parameters were observed when comparing emissions from test cigarettes with emissions from additive-free reference cigarettes, only two of the additives (sorbitol and guar gum) tested led to significant increases in a limited number of smoke constituents. These changes were not observed when sorbitol or guar gum were tested in a mixture with other priority additives. None of the priority additives resulted in increases in in vitro toxicity (Ames, Micronucleus, Neutral Red Uptake) or led to changes in smoking behavior or absorption (rate or amount) of nicotine measured during the human clinical study as compared to the additive-free reference cigarette. 
The use of additives in tobacco products
The cigarette industry uses tobacco additives in some types of cigarettes -typically American style blends -to balance the natural tobacco taste, to replace sugars lost in curing and give individual brands their characteristic tobacco flavor and aroma. Other additives control moisture, protect against microbial degradation and act as binders or fillers (Carmines, 2002; Dempsey et al., 2011; Rodgman, 2002) . Humectants are added to the tobacco to improve the moisture holding capacity of tobacco and thus the shelf life of cigarettes, (e.g., propylene glycol, sorbitol, and glycerol). Simultaneously, these humectants serve to, e.g. reduce breakage of the tobacco leaves and to facilitate cutting. Additives are also added either as casing 1 material to the tobacco leaves (e.g. cocoa, licorice) or as top flavorings 2 to the cut tobacco (e.g. ger-
aniol, fenugreek).
Regulation of tobacco additives in Europe
In accordance with reporting obligations under the first European Tobacco Product Directive EU (Directive, 2001 /37/EC, frequently referred to as TPD1) tobacco companies have submitted over the last 15 years available toxicological data on tobacco additives to EU Member States and -over and beyond the legal reporting obligations -results of internal, comprehensive Product Stewardship test programs that are aimed at ensuring that additives do not increase the inherent toxicity of tobacco products under normal conditions of use. These testing results have provided a wealth of information to support the conclusion that additives at current usage levels do not increase the inherent toxicity of tobacco products.
Art 6 (1) of the new Tobacco Products Directive (Directive, 2014/ 40/EU; herein, TPD2) requires enhanced reporting obligations, which apply to a selection of additives 3 contained in cigarettes and Roll Your
Own tobacco. According to Art 6 (2), Member States shall require manufacturers and importers of cigarettes and Roll Your Own tobacco containing an additive that is included on a so-called priority list to carry out comprehensive studies, which shall examine for each additive whether it: a) contributes to the toxicity or addictiveness of the products concerned, and whether this has the effect of increasing the toxicity or addictiveness of any of the products concerned to a significant or measurable degree; b) results in a characterizing flavor; c) facilitates inhalation or nicotine uptake; or d) leads to the formation of substances that have CMR 4 properties, the quantities thereof, and whether this has the effect of increasing the CMR properties in any of the products concerned to a significant or measurable degree.
Following the implementation of the new TPD2 and in preparation for the adoption of a priority list of additives, mentioned hereinafter, the European Commission (EC) requested the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) to "assist the Commission in identifying the additives that should be put on the priority list in line with Article 6 of TPD2." 5 On May 18, 2016, the EC published Commission Implementing Decision (EU) 2016/787 including a priority list of 15 additives, 6 based on the assessment provided by SCENIHR (Opinion 1). 7 The rationale for the selection includes (i) available data suggesting that an additive may fall into one of the four categories abovementioned and (ii) additives that are amongst the most commonly used additives in cigarettes and RYO tobacco by weight or number. Table 1 provides the list of the 15 priority additives, for which the enhanced reporting obligations apply. Pursuant to Article 6 of TPD2, the EC also asked the SCENIHR (Opinion 2) to advise on (i) "the type and criteria for comprehensive studies that should be requested from manufacturers to assess the relevance of the individual additives." (ii) "the most suitable methodologies to be used" in manufacturers' studies.
As the successor to the SCENIHR, the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) provided an opinion related to a testing strategy to assess the effect of additives used in cigarettes on (i) tobacco product toxicity, (ii) tobacco product "addictiveness" 8 or adding a characterizing flavor or facilitating inhalation or nicotine uptake.
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In conclusion, the approach that was taken for the assessment of priority additives according to Article 6 of TPD2 was to test 13 priority additives within the tobacco matrix and under use conditions relevant to cigarette consumption.
Study organization
To fulfil the legal requirements outlined above, in terms of providing scientific data, twelve major tobacco companies from the EU formed a "Priority Additives Tobacco Consortium". They identified thirteen tobacco additives from the above-mentioned priority List as used in their products and commissioned and financed the required studies: British American Tobacco (Investments) Limited, Continental 
Additives tested
The priority List specified 15 additives subject to enhanced reporting obligations. Two of them are not covered by this publication: The four lead companies originally forming the consortium (PMI, JTI, Imperial and BAT) resolved to exclude Diacetyl from testing as they do not use this additive in their cigarettes or Roll Your Own products. Titanium dioxide is only used as a whitening agent in non-tobacco material, which is closely embedded in the cellulose acetate fibers of the cigarette filters or in the tipping paper and therefore is not combusted. The results for titanium dioxide were part of the submission to the authorities but are not reported in this publication. Thus 13 additives were tested in the program as outlined in Table 2 .
The individual additives were ordered in the usual supply process (using industry suppliers). All additives were food grade additives, which were certified to be compliant with the requirements of the European regulation or equivalent obligations (European Union, 2008) . The specifications of the additives are described in Table 3 .
In addition to the certificates of analyses, which were obtained from the suppliers of the additive, further analyses were performed on the six additives which are extracts of plant material (carob bean, cocoa, fenugreek, fig, guar gum, liquorice extract) by two independent contract organizations (Yordas Group, UK and UFAG Laboratory, Switzerland) to determine those constituents of relevanceas requested by EFSA for botanicals and botanical preparation (EFSA, 2009) . The results of these analyses are presented in Supplemental Tables S1a-f. For Good Laboratory Practice (GLP) purposes the individual additives were suitably well characterized. Some variation was seen in the results reported between the two laboratories, and may be related to various reasons including the use of different methodologies by the laboratories and operator variation, as both laboratories were supplied exactly the same samples.
The test and additive-free reference cigarettes were manufactured by British American Tobacco (BAT). Additives were added to the tobacco as flavorings or casings as in the standard process of manufacturing, apart from guar gum which was added as usual in the form of cast leaf, i.e., as a cut tobacco sheet consisting of ground tobacco with guar gum as a binder. The cast sheet was prepared by Philip Morris Products SA in Neuchatel, Switzerland. The additive levels in the test cigarettes were defined to cover a broad range of concentrations based on the Quantity Not Exceeded (QNE) level used by the steering committee companies (PMI, BAT, JTI, Imperial), i.e., the highest concentration used in any of the products manufactured for sale in the EU by the sponsoring companies. The QNE level concentration is referred to as "Max" level in these studies. In addition, test cigarettes were manufactured with a "Low" and a "Max plus" level of additive added. The "Low" level was 50% of the Max level, and the Max plus level was 150% of the Max concentration. In cases where the Max plus concentration was technically not achievable due to restrictions of the manufacturing, the highest achievable concentration was used.
According to the study design, 43 different experimental cigarettes were manufactured: (1 additive-free reference cigarette, 42 test cigarettes: 13 additives added at 3 different levels resulting in 39 samples and 3 samples with various mixtures of additives (Mix 1, Mix 2, and Mix 3) referred to in Table 4 ). Where analytical methods for the quantification of the respective additive were available, inclusion rates were analyzed at the independent contract research organizations Aroma Labs (Planegg, Germany) or Eurofins (Switzerland).
Aroma Labs (Planegg, Germany) and LabStat (Canada) determined the transfer rates from the tobacco into the smoke. These data are reported in Part 2 paper of this series (Stabbert et al., 2019) .
Assessment approach

Literature reviews
A systematic literature review of published studies assessing the impact of additives in combusted tobacco products was conducted by KSR (Kleijnen Systematic Reviews Ltd, York, UK), following the highest standards and to meet best practice (Centre for Reviews and Dissemination, 2018; Higgins and Green, 2008) and submitted to the competent authorities in the EU, but only described in short in this series of publications. The searches were performed by information specialists in the relevant databases, e.g. Embase (Ovid) and MEDLINE (Ovid) (MEDLINE is the primary component of PubMed; what sets MEDLINE apart from the rest of PubMed is the added value of using the National Library of Medicine controlled vocabulary), using search terms and strategies developed specifically for each database (Kleijnen and Knipschild, 1992) . In addition, REACH and EFSA documents were identified at the agencies' websites. The search strategies were No valid methods exist to evaluate whether additives have a direct effect on the addictiveness of final tobacco products. To assess the impact of additives on inhalation, nicotine uptake and smoking behaviour, the following methodologies were used in a human clinical
• PK (pharmacokinetic) studies to measure nicotine uptake • Smoking behaviour studies SCHEER notes that no validated models are available for the assessment of addictiveness, but suggests numerous nonvalidated methods with questionable relevance for the endpoints to be examined. Some of the tests proposed are based on mathematical computer models for prediction e.g.,
• Computer models: in silico QSAR In combination with in vitro three-dimensional tissue constructs "results in a characterising flavour"
• Sensory testing
• Sensory testing Simms, et al. Regulatory Toxicology and Pharmacology 104 (2019) 84-97 independently peer reviewed by an information speacialist using the Evidence Based Checklist for the Peer Review of Electronic Search Strategies, PRESS EBC (Canadian Agency for Drugs and Technologies in Health 2017 websites). All references in identified studies were checked for information of further evidence. Clearly defined acceptance/inclusion criteria determined inclusion into the final compilations of references. These compilations included the aims and overall conclusions of the authors and the objective study outcomes (See Fig. 1 ). Fig. 1 . Example of the flow diagram used for the selection of publications for the priority additive Menthol.
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Comparative testing
The studies described in this publication tested whether tobacco additives increase the toxicity, CMR properties to a significant or measurable degree, facilitate inhalation or nicotine uptake or result in a characterizing flavor by applying a comparative testing approach. This approach follows directly from Article 6(2) Tobacco Products Directive (European Union, 2014) that provides that the manufacturers are required to examine for each additive on the priority list whether it:
"(a) contributes to the toxicity or addictiveness of the products concerned, and whether this has the effect of increasing the toxicity or addictiveness of any of the products concerned to a significant or measurable degree; (d) leads to the formation of substances that have CMR properties, the quantities thereof, and whether this has the effect of increasing the CMR properties in any of the products concerned to a significant or measurable degree."
Under the same Directive Article 7(9), these examinations shall enable Member States to take an informed decision to:
"prohibit the placing on the market of tobacco products containing additives in quantities that increase the toxic or addictive effect, or the CMR properties of a tobacco product at the stage of consumption to a significant or measurable degree." Thus, the EU Directive and the subsequent national legislations ask for a comparative testing approach, as an increase in toxicity/property can only be determined, when the baseline toxicity/property of a cigarette without the additive (reference cigarette) and that of a cigarette with the additive (test cigarette) is quantified and then compared to each other in a valid statistical test. Beside these legislative considerations, the comparative testing approach was and is the generally accepted valuation method in the scientific literature (Carmines, 2002; Dempsey et al., 2011; DIN Deutsches Institut für Normung, 2014; Renne et al., 2006) .
Cigarette construction
The cigarettes were manufactured by British American Tobacco Germany within the parameters of those sold in the EU. They were high speed machine-made, 1200-1500 cigarettes/min (Molins Mark 9/ Hauni Max S, Hauni Maschinenbau, Germany), per standard commercial cigarette production, i.e., cellulose acetate filter cigarettes using a typical American blend of tobacco with 60% Virginia, 28% Burley, and 12% Oriental tobacco. 15.1% of the tobacco was given in form of expanded tobacco and 13.6% in form of cut rolled stems. The cigarettes were laser ventilated at 37%. They were packed as conventional retail cigarettes in 20-cigarette card boxes wrapped in polypropylene.
The cigarettes were manufactured to a standard rod firmness which is representative of commercial manufacture. To achieve the target firmness value the tobacco weight was adjusted to compensate for the addition of the selected additive where necessary. This means that all of the cigarettes in the test batches are within a set total weight tolerance. The percentage inclusion quoted was based upon measured addition (w/w) to the tobacco pre-manufacture, or by analytical measurement post manufacture, dependent upon the additive. For each of the 42 test cigarettes there was found to be no significant difference compared to the additive-free reference cigarette with regard to their physical characteristics (e.g., tobacco weight, moisture, firmness, resistance to draw, ventilation (Supplementary Tables S2a-b) .
The monitor cigarette 3R4F, was purchased from the University of Kentucky. (Kentucky, USA).
Selection and execution of assays
When available, the assays chosen were standard assays that are used to evaluate a broad spectrum of products, e.g., medicals, food and consumer products including tobacco products. For most of them, their methodology has been laid down in detail in guidelines, e.g. those of the OECD, which are considered to be mandatory for each laboratory performing these assays. These guidelines are harmonized between the different legislations worldwide (also compliant with those published by the International Conference on Harmonization).
The studies were carried out in independent Contract Research Organizations (CROs) under Good Laboratory Practice (GLP) guidelines, compliant to those laid down in the pertinent regulations (European Commission, 1999 ).
An overview of the testing program is presented in Table 5 .
Pyrolysis
Pyrolysis experiments with neat tobacco additives have been performed since the 1950s to investigate the relationships between smoke constituents and their precursors in tobacco (Wynder et al., 1958; Baker, 1987; Baker and Bishop, 2004, 2005; Chortyk and Schlotzhauer, 1973; Purkis et al., 2011; Schlotzhauer and Chortyk, 1987) . Pyrolysis experiments were used as research tools and standardized, validated methods were not implemented due to the complex, dynamic processes occurring inside a burning cigarette, which are difficult to mimic with standardized experimental pyrolysis conditions. For most of the priority additives, there is pyrolysis data in the published scientific literature (Baker and Bishop, 2004, 2005; Purkis et al., 2011) . Thus, it does not seem helpful to add further data derived from unvalidated methods. Purkis et al., e.g., conducted a mass balance study on radiolabelled key additives. The unaccounted material, which was not transferred intact in the studies of both volatile and non-volatile additives, was primarily transformed into products of complete combustion such as simple gases as carbon monoxide or carbon dioxide with only very minor amounts being transformed into products of incomplete combustion. In addition, the studies on both unlabelled and deuterium labelled compounds demonstrated that the utility of pyrolysis studies lies in distinguishing between those compounds that transfer intact into mainstream smoke from those that might be liable to degrade. Purkis et al. (2011) , concluded that pyrolysis does not provide a robust prediction of the compounds that are formed from additives during cigarette smoking studies.
To evaluate whether additives impact the chemistry or toxicity of the tobacco smoke to a significant or measurable degree, as required by Article 6(2) of the TPD (2014/40 EU) comparative chemical analyses and biological assays analyzing were performed to assess if any potential changes in smoke chemistry parameters translates into differences in toxicology (Carmines, 2002) .
Smoke chemistry
Smoke was generated from all cigarettes according to ISO standards 3308 and 4387 (ISO-3308, 2000; ISO-4387-4, 2000) . This smoking regimen is the standard regimen in the EU for, e.g., reporting smoke L. Simms, et al. Regulatory Toxicology and Pharmacology 104 (2019) 84-97 emissions of cigarettes. Furthermore, this smoking regimen appears to be more efficient in detecting possible differences in the yield of smoke toxicants than more intense smoking regimens (Roemer and Carchman, 2011) . The authors could demonstrate that intense smoking regimens decrease the concentration of toxicants in the smoke per unit mass of mainstream smoke, tar, and nicotine. This is probably due to a more complete combustion, decreasing differences in toxicity observable under ISO and leading to more uniform concentrations of emissions for different cigarettes. Chemical analyses were performed quantifying 39 smoke emissions (plus tar, water and where demanded menthol, glycerol, and polypropylene glycol) that are regarded by the World Health Organization to be of priority emissions for further regulations (WHO, 2015) .
The analyses were performed under GLP according to recognized, validated, and standardized methods as defined by Health Canada for regulatory purposes of tobacco products. (Methods are available on request at https://www.canada.ca/en/health-canada/services/healthconcerns/tobacco/legislation/federal-regulations/tobacco-reportingregulations.html). The analyses were carried out by the independent testing CRO LabStat in Canada.
In vitro assays
The three in vitro toxicity assays employed in this study were the Neutral Red Uptake Assay (NRU), Ames Assay, and in vitro Micronucleus (ivMN) assay, which are standard assays used to assess the toxicity (cytotoxicity, mutagenicity, and genotoxicity) of broad spectrum of materials, including pharmaceuticals, food, industrial chemicals.
Data from these in vitro assays are mandatory in the legislation of certain countries to be presented by the manufacturers of these materials for review. These assays have been used as standard to assess the impact of product changes and modifications, or the contribution of certain components of cigarettes, such as additives, to the toxicity of cigarette smoke over the past two decades, e.g. Bombick et al., 1997; Carmines, 2002; Coggins et al., 2011j; Combes et al., 2012; Crooks et al., 2018; Dempsey et al., 2011 ; DIN Deutsches Institut für Normung, 2014; Doolittle et al., 1988; Gaworski et al., 1998; Heck, 2010; Massey et al., 1998; Oldham et al., 2013; Oldham et al., 2012; Paschke et al., 2002; Purkis et al., 2011; Rodgman, 2002; Roemer et al., 2012; Takahashi et al., 2018) . Some regulations, e.g., in Canada, explicitly require the evaluation of tobacco products in these in vitro assays.
The analyses were performed under GLP according to recognized, validated, and standardized methods as defined by Health Canada for regulatory purposes of tobacco products. (methods can be requested at https://www.canada.ca/en/health-canada/services/health-concerns/ tobacco/legislation/federal-regulations/tobacco-reporting-regulations. html). The analyses were carried out by the independent testing CRO Labstat in Canada.
In the NRU, the Total Particulate Phase (TPM, trapped on glass fiber filters) and gas/vapor-phase (GVP, trapped in phosphate buffered saline) of the mainstream smoke were tested separately, in Chinese Hamster Ovary (CHO-WBL IVGT)) cells. The concentration of the TPM or GVP that reduced the number of cells to 50% of that found in the control was used as the parameter to characterize the cytotoxicity of the smoke.
In the Ames assay, the TPM of the mainstream smoke was tested in 5 strains of Salmonella typhimurium (TA98, TA100, TA102, TA1535, TA1537) in the presence (+S9) and absence (-S9) of a metabolic activation system. The linear slope of the dose/response curve was used as the parameter to characterize the mutagenicity of the smoke.
In the in vitro Micronucleus Assay (ivMN), the particulate phase of the mainstream smoke was applied directly to Chinese Hamster Ovary (CHO-WBL (IVGT)) cells. The linear slope of the dose/response curve was used as the parameter to characterize the genotoxicity (aneugens and clastogens) of the smoke by comparing TPM of the additive-free reference cigarettes to the test cigarette containing the additives.
In vivo assays
For ethical reasons, animal testing is expressly forbidden for tobacco products in several EU member states (European Union, 2010).
A vast amount of published peer reviewed studies demonstrates that additives do not increase the inherent in vivo toxicity of cigarette smoke.
These include several sub-chronic inhalation studies that have clearly demonstrated that the addition of additives, including the priority additives, added at levels used by the tobacco industry, do not increase the inherent inhalation toxicity potential of the smoke, either when added to the tobacco as single additives or as part of flavor mixtures Carmines, 2002; Coggins et al., 2011a Coggins et al., , 2011b Coggins et al., , 2011c Coggins et al., 2011e; Coggins et al., 2011f; Coggins et al., 2011g; Coggins et al., 2011h; Coggins et al., 2011i; Coggins et al., 2011j; Renne et al., 2006; Schramke et al., 2014; Vanscheeuwijck et al., 2002) .
With regard to reproductive and developmental toxicity, there are no published data in the literature to suggest that tobacco additives have an impact on these toxicities. In vivo studies for investigating the effects of cigarette smoke on reproduction in animals, have poor predictivity for reproductive effects in humans (Bailey et al., 2005) and it was shown that studies conducted in pregnant rats exposed to tobacco L. Simms, et al. Regulatory Toxicology and Pharmacology 104 (2019) [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] smoke for predicting human reproductive and developmental end points had limited relevance (Carmines et al., 2003; Carmines and Rajendran, 2008; Gaworski et al., 2004) . Notably, none of the Priority additives are classified under the CLP Regulation (EC No. 1272 as toxic to reproduction. Accordingly, no further in vivo studies were performed.
Facilitating inhalation or nicotine uptake
The Priority Additives Tobacco Consortium commissioned a randomized, controlled, double-blind clinical study to examine the effects of different priority additives added either individually or as part of mixtures to cigarettes on nicotine pharmacokinetics to determine whether the presence of the additive increased nicotine uptake or influenced smoking behavior. Plasma nicotine pharmacokinetics and analyses of changes in smoker puffing behavior were used to determine whether the addition of additives in the tobacco facilitated inhalation or nicotine uptake. In addition, both end points can be considered to be surrogate markers of the potential to contribute to addictiveness. Thus, they are addressing in particular a concern by SCHEER regarding identifying those additives that are able to facilitate inhalation or nicotine uptake via the lung.
With regard to human studies, this is in line with the recommendation made by SCHEER (SCHEER, 2016) regarding nicotine analysis as a biomarker of exposure. Although there have been discussions on additional tests for addictiveness of additives, further investigation of such methods has led the Priority Additives Tobacco Consortium to conclude that there are no other alternative tests that would provide meaningful information on the addictiveness potential of the priority additives. It has been stated, "Due to these limitations, the available methodologies are not considered adequate" (SCENIHR, 2010) .
With regard to animals studies, SCHEER (SCHEER, 2016) stated that "current tests to analyse dependence potential can monitor self-administration, speed of acquisition, conditioned rewarding effects and drug discrimination", as well as severity of withdrawal. However, the scientific committee also highlighted that these tests are currently only designed to assess nicotine dependence, not dependence of tobacco additives or tobacco products as a whole. While the SCHEER suggested to adapt the available models "to assess the effect of (nicotine in combination with) other tobacco-related additives on dependence", they did not elaborate on the requirements for such an adaptation. However, no further details are provided on the requirements for such an adaptation. Even if such adaptations were feasible, there are still several important caveats which need to be considered when extrapolating results from animal studies to humans. Examples include differences in nicotine pharmacokinetics between species or potential unintentional stress factors, such as restraint acclimation (Thompson et al., 2018) . Critically, these assays are not validated and do not have any well-defined methodology making the determination of any difference to a statistically significant degree very difficult to determine.
With regard to in vitro assays, FDA, on their guidance to industry on the potential abuse assessment of drugs (FDA, 2017) , was unable to identify any suitable in vitro assays for assessing the "abuse"/dependence potential of new or existing compounds.
Ten priority additives were chosen based on suspected effects on nicotine kinetics (inhalation depth, or total nicotine absorbed, or time to reach maximal concentration) as identified by SCHEER, (SCHEER, 2016) : carob bean, cocoa, fenugreek, fig, glycerol , guaiacol, liquorice, menthol, propylene glycol, sorbitol, and a mixture of additives. The other three additives (geraniol, guar gum and maltol) along with 8 of the 10 single additives were tested in Mix 3 together, to look at possible effects of interactions between the individual additives.
The analyses were performed under GLP according to recognized, validated, and standardized methods with 48 smokers according to the ethical requirements referred to in the European Union (EU) directive 2001/20/EC and the ethical principles set forth in the Declaration of Helsinki. The analyses were carried out by the independent testing contract research organization Celerion in Northern Ireland.
Addictiveness testing
To examine if the priority additives added either individually or as part of mixtures to cigarettes, facilitates inhalation or increases nicotine uptake, two distinct end points were investigated, namely measuring plasma nicotine pharmacokinetics as a measure of nicotine uptake and analysis of changes in smoker puffing behavior as a measure of changes in cigarette smoke inhalation. The Priority Additives Tobacco Consortium concluded that there were no other alternative tests that would provide meaningful information on the addictiveness potential of the priority additives. The rationale for this decision is described as follows.
Addictiveness is defined in the context of Art (2) SCENIHR (Scientific Committee on New Identified Health Risks) concluded that no tobacco additives that were addictive by themselves had been identified. The scientific committee acknowledged that experiments which would potentially quantify the effects of additives on tobacco product addictiveness "require large technical and financial resources. In addition, there are ethical issues if testing in humans is considered. Due to these limitations, the available methodologies are not considered adequate" (SCENIHR, 2010) .
In the 2016 "Opinion on additives used in tobacco", SCHEER stated that "experimental testing of the dependence potential of tobacco additives is still limited due to the lack of validated administration models for the examined individual compound itself and in co-administration with other tobacco additives". In the absence of such validated tests, the scientific committee proposed a step-wise approach strategy to "experimentally quantify the dependence potential of tobacco additives (often) co-administered with nicotine" based on in silico, in vitro, in vivo and ex vivo studies. Some of the assays highlighted as part of this approach are also discussed in a related paper released by van de Nobelen et al. (2016) . SCHEER also suggested the potential use of imaging techniques (fMRI, PET and SPECT) to investigate changes in neurobiological effects as a result of tobacco consumption.
Due to the lengthy validation process, it is highly improbable that these assays will become accepted and validated in the next few years. Therefore, in the absence of any clear guidance or evidence on what results would satisfy the remit of addictiveness testing as per Art (6) of Directive 2014/40/EU, no further studies were performed.
Characterizing flavor analysis
The priority additives Tobacco Consortium commissioned a sensory analysis study to an independent CRO in Germany to determine if test cigarettes with selected priority additives led to a characterizing flavor. There is no validated and commonly accepted methodology for the assessment if a tobacco product develops a clearly noticeable smell or taste (characterizing flavor) other than one of tobacco resulting from an additive or a combination of additives. Accordingly, a sensory methodology was developed by an expert in sensory analysis. In this methodology the products were smelled and not smoked (see Fig. 3 ).
Eight of the tobacco additives were tested, that were deemed by the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER, 2016) to potentially result in a characterizing flavor other than tobacco when added to tobacco products. The selected priority additives were tested at the Low and Max addition levels: priority additives tested were: carob bean, cocoa, fenugreek, fig, geraniol , guaiacol, liquorice and menthol.
The study was carried out under ISO/IEC 27001 by the independent testing CRO SAM (Sensory and Marketing International) GmbH in Germany. The study will be published in another journal with special focus on sensory research.
The principle methodology and a short summary of key results are given below, the complete study will be published elsewhere:
Stage 1: Identification of the reference products and clustering according to sensory attributes. The following products were selected for the sensory study:
• 45 in-market reference products were selected, not having a characterizing flavor according to the TPD2 definition and being representative of different tobacco blend types from the EU market.
• 6 menthol products from the EU market (having a characterizing flavor but being exempted from the characterizing flavor ban until 2020).
• 4 products with different characterizing flavors (sampled in nonEuropean markets) as positive controls were selected.
• Furthermore, 17 test cigarettes containing the 8 priority additives in two concentrations (Low and Max) and one additive-free reference cigarette were added to be assessed in the study. Three trained panelists identified the sensroy properties of all 72 products and were then used for the next step, clustering of all products by 15 consumers who were screened and selected for their sensory ability. Stage 2: Screening using an 'In/Out' test.
• 10 consumers were screened and selected for their sensory capability, evaluated 22 products (17 test products/prototypes and 5 positive controls) in order to determine if their sensory attributes fell within the range of the reference cigarette space ('In') or are judged to be different ('Out'). Stage 3: Sensory analysis using CATA (Check-All That Apply) testing for the products rated as 'Out' in the previous stage.
• 40 consumers were screened and selected for their sensory ability, evaluated the products that were rated 'Out' in the 'In/Out' test and 15 reference products (included for the calculation of control values representative of products without characterizing flavor) with regard to the presence of the sensory attributes identified in stage 1 of the test. Stage 4: Analysis of the CATA data.
• All positive controls and the test products were compared to the control values, for sensory attributes determined for the 15 reference products.
Presentation of results
As predefined in the GLP study protocols, smoke chemistry results were presented on a yield per cigarette basis. As the total particulate mass as well as the nicotine delivery of the test and the additive-free reference cigarette were practically identical, this presentation is equivalent to analyte yield per mg TPM or per mg nicotine.
Toxicological data were presented per mg TPM as the common unit of measure for this kind of data in the scientific literature.
Statistics
When comparing chemistry and in vitro data of the test and control cigarettes measured in replicates, common hypothesis test techniques, such as t-test or analysis of variance (ANOVA), were used (see Fig. 2 ). These statistical tests rely on the observed variability of the test and control data as the best estimate for the variance of the data set derived under a specified method. However, just by chance, the data in both groups might cluster rather narrow around their means; far less than an experienced expert might normally expect, knowing the inherent variability of the method in his laboratory. This may lead to statistical significances between two means that are rather minute and well within the known variability of the method. To deal with this phenomenon, which goes beyond the expected false positive and false negative outcomes and in absence of suitable statistical tools, equivalence ranges (also termed minimal detectable differences or critical difference) for each analyte and in vitro assay result were calculated based on the empirical long-term variability of the 3R4F monitor cigarette, which essentially provides the inherent precision of the analytical method over time (Belushkin et al., 2015; Oldham et al., 2012; Roemer and Carchman, 2011) . These ranges are in consensus with equivalence ranges developed for other industries (FDA, 2001) . In our studies, the 3R4F monitor cigarette 12 Month-Variability determined by LabStat was used to specify the equivalence ranges. Given that the University of Kentucky produced the 3R4F monitor cigarettes at a single point in time from a single set of tobacco lots, the agricultural and manufacturing L. Simms, et al. Regulatory Toxicology and Pharmacology 104 (2019) 84-97 variability components can be considered as minimal. All differences in means lying within these ranges were therefore screened out as being not meaningful. When comparing pharmacokinetic parameters and smoking behavior endpoints, a mixed model with repeated measurements was used.
Results and discussion
Literature reviews
As a result of the systematic electronic database searching for toxicity studies of all priority additives, when added to tobacco, a total L. Simms, et al. Regulatory Toxicology and Pharmacology 104 (2019) [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] of 10,863 records were identified. After de-duplication of the library, 6,097 records remained; these were screened at the title and abstract stage to identify studies that were potentially relevant to any of the 13 additives. Manual searches and other sources provided an additional number of records. From all, 287 records were selected to be re-screened at the full paper stage. On completion of full paper screening, typically approximately 20 publications were finally included for the systematic review that dealt with the toxicology of the individual additive.
None of the publications identified gave rise to a concern, that the addition of additives might increase the inherent toxicity of the smoke.
Likewise, an extensive literature search was conducted to obtain a toxicological profile of the 13 selected priority additives in their neat unburnt form. The acute, chronic, reproductive and developmental toxicity, in addition to the mutagenic/genotoxic, carcinogenic and sensitization potential of each of the neat unburnt priority additives was researched. Furthermore, the commercial applications and regulatory assessment provided by various regulatory authorities, such as the Joint FAO/WHO Expert Committee on Food Additives (JECFA), European Food Standards Agency (EFSA) the Scientific Committee for Food (SCF), the Research Institute for Fragrance Materials (RIFM) and the Organization for Economic Cooperation and development (OECD) were presented as part of the literature search. If a regulatory assessment was not published by a regulatory authority for a selected priority additive, the open literature was used to obtain a toxicological profile. The food safety status of each additive according to the Food and Drug Administration and European Union was also considered. The classification of each additive according to the Classification, labelling and packaging (CLP) Regulation (EC) No. 1272/2008 was also provided to form a toxicological profile of each priority additive.
Some adverse effects were reported for a few animal studies and could be attributed to the extremely high dosages used for a single priority additive, fenugreek. This concerned possible reproductive effects when administered to rats at high dosages (100-1200 mg/kg/day) with no effects reported in humans. However, this had no relation to its usage under real life conditions and certainly not to the amounts applied to tobacco, Fenugreek is nonvolatile and does not transfer intact in to mainstream smoke.
The results of these searches were used to discuss the outcomes of our studies in the context of the comprehensive scientific knowledge already gathered on the use of tobacco additives.
Smoke chemistry
Comparisons of the composition of smoke from cigarettes with and without the additives in our studies gave some differences, which, with only few exceptions, were minor, well within the inherent variability of the analytical method and cigarette manufacturing, not statistically significant, and did not show consistent additive related increases or decreases (Stabbert et al., 2018) . The addition of glycerol and propylene glycol resulted in decreases of several smoke constituents. The cigarettes with the addition of guar gum showed significant increases for formaldehyde and cadmium, and test cigarettes containing sorbitol showed significant increases for formaldehyde and acrolein in the smoke. These changes were not observed when sorbitol or guar gum were tested in a mixture with other priority additives.
Noticeably, the above-mentioned increased smoke emission did not increase the in vitro toxicity of the smoke.
Overall, these results are in agreement with the published literature.
Transfer rates
For 7 of the additives (geraniol, glycerol, guaiacol, maltol, menthol, propylene glycol, and sorbitol) transfer rates from the filler of the cigarettes into the smoke were determined. Transfer rates of 2 additives (cocoa and liquorice) were determined for the lead substances in these botanicals (theobromine and glycyrrhizic acid). For 4 additives no such lead substances were available or the background levels from the tobacco its self was too high (carob bean, fenugreek, guar gum, and sorbitol). For detailed results see the second paper in this series (Stabbert et al., 2018) .
In vitro studies
Comparisons of the composition of smoke from cigarettes with and without the additives in our studies gave some differences, which, with only few exceptions, were minor, well within the inherent variability of the analytical method and cigarette manufacturing, not statistically significant, and did not show consistent additive related increases or decreases. Thus, it can be concluded that the addition of the priority additives did not increase the toxicity of the cigarette smoke.
In vivo studies
Inhalation studies
According to published studies, none of the priority additives increases the in vivo inhalation toxicity when added to the tobacco of cigarettes Coggins et al., 2011b Coggins et al., , 2011c Coggins et al., , 2011d Coggins et al., , 2013 Coggins et al., 2011j; Gaworski et al., 1998; Renne et al., 2006; Schramke et al., 2014; Vanscheeuwijck et al., 2002) . Actually, all authors concluded that the addition did not lead to any consistent and meaningful changes in the overall inhalation toxicity profile in rats.
Thus, also explained above, no further in vivo studies were carried out on the smoke of cigarettes with and without additives.
Reproductive toxicity
None of the 15 selected priority additives were classified as hazardous to reproduction under the Classification, labelling and packaging (CLP) Regulation (EC) No. 1272/2008 of the European Parliament and of the Council.
Regarding the reproductive toxicity of tobacco smoke, there are currently no meaningful animal-models available. Furthermore, chemical smoke analyses showed only minor differences between the cigarettes with and without additives, suggesting that there are also no differences in reproductive toxicity. Thus, no further studies were carried out on the smoke of cigarettes with and without additives.
Facilitating inhalation or nicotine uptake
Plasma samples were collected at multiple time points up to 240 min before and after subjects were smoking the additive-free reference cigarette and the test cigarettes, to evaluate nicotine PK parameters. Plasma nicotine PK profiles were well characterized for 240 min following the start of cigarette smoking and the statistical analyses of the resulting PK parameter estimations (C max T max AUC), were not statistically significantly different between the test cigarette with the additives and the additive-free reference cigarette for any of the priority additives tested (Mixed ANOVA p > 0.05). After the PK study, subjects smoked a cigarette ad libitum whilst various smoking parameters were measured. When a single cigarette with (Max addition level) and without the priority additive was smoked, there was found to be no effects on any of the smoking parameters measured and reported within Part 3 of this series of publications (McEwan et al., 2019) .
Thus, the results demonstrate that none of the priority additives facilitated inhalation or nicotine uptake. This conclusion is in agreement with the fact that the amounts of substances in the smoke that possibly could have an effect on these mechanisms are far too low to evoke any effect. The same results can also be taken as circumstantial evidence that the additives do not add to the addictiveness of cigarette smoke.
Addictiveness testing
As currently there are apparently no other alternative tests than those on smoking parameters and nicotine pharmacokinetics that would provide meaningful information on the addictiveness potential of tobacco additives, no studies were conducted on this endpoint. However, the transfer rates into the smoke of substances that possibly could have a psychoactive/pharmacological effect were determined. Our results on the transfer rates confirm the data published in the literature and show that the concentrations of these substances (glycyrrhizic acid, theobromine) are far too low to evoke any effect. Furthermore, the results of the studies on smoking behavior and nicotine pharmacokinetics, as surrogate markers for addictiveness, did not show differences between smoking cigarettes with and without additives.
Characterizing flavor analysis
The different sensory methodologies used (clustering, 'In/Out' test and CATA testing) revealed only menthol at the max level (1.2%) to have a characterizing flavor, menthol at 0.6% was not determined to be characterising. None of the other priority additives tested when smelled were deemed to be sensorially different from the control products. Test cigarettes were manufactured approximately two months prior to testing using high speed production techniques and stored in the packaging routinely used to package cigarettes. The two months gap between cigarette production and testing is typical of the time taken for cigarettes to get on to the market through normal supply channels. Menthol is moderately volaltile and is known to be lost from cigarettes over time. Ashley et al. (2012) did not condition menthol cigarettes prior to ISO smoking because of the known problems of menthol loss. The negative results for menthol at 0.6% could also reflect the loss of menthol over time through the packaging.
Conclusion
The data presented in this series of three papers shows the results of comprehensive studies required by EU TPD (2014/40/EU) Article 6(2) that were commissioned by a consortium of 12 tobacco companies to independent Contract Research Organizations (CROs). When comparing emissions from test cigarettes with and from additive-free reference cigarettes without priority additives, out of the 13 priority additives tested some minor increases or decreases in smoke chemistry parameters were observed,. In test cigarettes with sorbitol significant increases of formaldehyde and acrolein versus the additive-free reference cigarette were determined, while with guar gum formaldehyde and cadmium increased. These increases did not translate into increases in the in vitro toxicity and were also not observed when sorbitol or guar gum were tested in a mixture with other priority additives. None of the priority additives tested resulted in increases in in vitro toxicity (Ames, Micronucleus, Neutral Red Uptake) or led to changes in smoking behavior or nicotine absorption or uptake (rate or amount) measured during the human clinical study as compared to the additive-free reference cigarette.
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